 compar trial doxorubicin treatment malign pleural effus secondari lung cancer efficaci safeti intrapleur yakult tokyo japan doxorubicin adriamycin adria columbu OH random trial patient malign pleural effus lung cancer seventy-six patient elig assess efficaci respons rate treatment intrapleur doxorubicin patient respons rate control group doxorubicin patient group improv perform statu PS symptom pain chest discomfort anorexia control group signific prolong surviv group main side effect transient hepat dysfunct seriou advers reaction result intrapleur instil treatment malign pleural effus